Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis

Pharmacogenetics and Genomics

Volumn 15, Issue 5, 2005, Pages 349-355

  Halsall, J A ^a   Osborne, J E ^b   Pringle, J H ^a   Hutchinson, P E ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Psoriasis susceptibility; Psoriasis treatment; VDR; VDR polymorphisms

Indexed keywords

CALCIPOTRIOL; COLECALCIFEROL; TRANSCRIPTION FACTOR GATA 3; VITAMIN D RECEPTOR;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; EPIDERMIS; FAMILY HISTORY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HUMAN; IMMUNOREACTIVITY; KERATINOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS; TH1 CELL;

EID: 18744409798     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200505000-00011     Document Type: Article

References (49)

1. Van Scott EJ, Ekel TM. Kinetics of hyperplasia in psoriasis. Arch Dermatol 1963; 88:373-380.
2. Fry L, McMinn RMH. Observations on mitoses in psoriatic epidermis. Br J Dermatol 1970; 82:19-22.
3. Van Scott EJ. Morphologic and physiological effects of chemotherapeutic agents in psoriasis. J Invest Dermatol 1959; 33:357-369.
4. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-2074.
5. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139:390-395.
6. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113:752-759.
7. Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha, 25-dihydroxyvitamin D3. Endocrinology 1983; 113:1950-1957.
8. Smith EL, Walworth NC, Holick MF. Effect of 1,25-dihydroxyvitamin D3 on the morphological and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86:709-714.
9. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15:2579-2585.
10. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8:174-179.
11. Mathieu C, van Etten E, Decallonne B, Guilietti A, Gysemans C, Bouillon R, Overbergh L. Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J Steroid Biochem Mol Biol 2004; 89-90:449-452.
12. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206:1188-1190.
13. Feldman D, Chen T, Hirst M, Colston K, Karasek M, Cone C. Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. J Clin Endocrinol Metab 1980; 51:1463-1465.
14. Milde P, Hauser U, Simon T, Mall G, Ernst V, Haussler MR, et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 1991; 97:230-239.
15. Solvsten H, Fogh K, Svendsen M, Kristensen P, Astrom A, Kumar R, Kragballe K. Normal levels of the vitamin D receptor and its message in psoriatic skin. J Invest Dermatol Symp Proc 1996; 1:28-32.
16. Kragballe K, Gjertsen B, DeHoop D, Karlsmark T, vanDe Kerkhof P, Larko O. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337:193-196.
17. Chen ML, Perez A, Sanan DK, Heinrich G, Chen TC, Holick MF. Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol 1996; 106:637-641.
18. Uitterlinden AG, Pols HA, Burger H, Huang Q, Van Daele PL, Van Duijn CM, et al. A large-scale population-based study of the association of vitamin D receptor gene polymorphisms with bone mineral density. J Bone Miner Res 1996; 11:1241-1248.
19. Ingles SA, Haile RW, Henderson BE, Kolonel LN, Nakaichi G, Shi CY, et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol Biomarkers Prev 1997; 6:93-98.
20. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367:284-287.
21. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338: 143-156.
22. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HTL, et al. Are human vitamin D receptor gene polymorphisms functionally significant? In: Norman AW, Bouillon R, Thomasset M (editors): Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects. Riverside, California: University of California; 2000, pp. 817-823.
23. Saijo T, Ito M, Takeda E, Huq AH, Naito E, Yokota I, et al. A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: Utility of single strand conformation polymorphism analysis for heterozygous carrier detection. Am J Hum Genet 1991; 49:668-673.
24. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 2000; 14:401-420.
25. Halsall JA, Osborne JE, Potter L, Pringle JH, Hutchinson PE. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br J Cancer 2004; 91:765-770.
26. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today 2000; 21:479-483.
27. Kontula K, Valimaki S, Kainulainen K, Viitanen AM, Keski-Oja J. Vitamin D receptor polymorphism and treatment of psoriasis with calcipotriol. Br J Dermatol 1997; 136:977-978.
28. Mee JB, Cork MJ. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J Invest Dermatol 1998; 110:301-302.
29. Park B-S, Park J-S, Lee D-Y, Youn J-I, Kim I-G. Vitamin D receptor polymorphism is associated with psoriasis. J Invest D 1999; 112:113-116.
30. Lee DY, Park PS, Choi KH, Jeon JH, Cho KH, Song KY, et al. Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients. Arch Dermatol Res 2002; 294:1-5.
31. Okita H, Ohtsuka T, Yamakage A, Yamazaki S. Polymorphism of the vitamin D(3) receptor in patients with psoriasis. Arch Derm Res 2002; 294: 159-162.
32. Saeki H, Asano N, Tsunemi Y, Takekoshi T, Kishimoto M, Mitsui H, et al. Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulagaris. J Dermatol Sci 2002; 30:167-171.
33. Holick MF, Chen ML, Kong XF, Sanan DK. Clinical uses for calcitropic hormones 1,25-dihydroxyvitamin D3 and parathyroid hormone-related peptide in dermatology: a new perspective. J Invest Dermatol Symp Proc 1996; 1:1-9.
34. Schneider S, Roessli D, Excoffier L. Arlequin: Software for Population Genetics Data Analysis, version 2.000. Geneva: Genetics and Biometry Lab, Department of Anthropology, University of Geneva; 2000.
35. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol 1994; 130:216-224.
36. Sagoo GS, Tazi-Ahnini R, Barker JW, Elder JT, Nair RP, Samuelsson L, et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 2004; 122: 1401-1405.
37. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6:813-820.
38. Nair R, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997; 6:1349-1356.
39. Tazi Ahnini R, Camp N, Cork M, Mee JB, Keohane SG, Duff GW, di Giovine FS. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Hum Mol Genet 1999; 8:1135-1140.
40. Asumalahti K, Laitinen T, Itkonen-Vatjus R, Lokki ML, Suomela S, Snellman E, et al. A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum Mol Genet 2000; 9:1533-1542.
41. Holm SJ, Carlen LM, Mallbris L, Stahle-Backdahl M, O'Brien KP. Polymorphisms in the SEEK1 and SPR1 genes on 6p21.3 associate with psoriasis in the Swedish population. Exp Dermatol 2003; 12:435-444.
42. The International Psoriasis Genetics Study. Assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am J Hum Genet 2003; 73:430-437.
43. Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004; 13:R43-R55.
44. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13:450-456.
45. Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164:2405-2411.
46. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164:4443-4451.
47. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995; 15: 5789-5799.
48. Cippitelli M, Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 1998; 28:3017-3030.
49. Klosner G, Trautinger F, Knobler R, Neuner P. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol 2001; 116:459-462.